Skip to main content

Topic

Drug Labeling

96 published works

  1. Drug & Device Law

    Adverse Event Reports Not Newly Acquired Information for CBE Label Change

    By Michelle Yeary

    Today’s case is a favorable prescription drug preemption decision making a key holding on newly acquired information and adverse event reporting.  It is a one-off case involving the prescription drug…

  2. Health Care and Life Sciences

    Southern District of New York Puts Non-Drowsy Labeling Claims To Bed

    By Michelle Yeary

    It’s the start of cold and flu season, so why not talk about cough syrup.  Most cough medicines come in two versions – daytime and nighttime.  The nighttime version typically…

  3. Drug & Device Law

    Failure-to-Warn Claim Targeting Branded Drug Held Preempted:  Litigation-Driven Expert Analysis Is Not “Newly Acquired Information” for Purposes of the “Changes Being Effected” Regulation

    By Andrew Tauber

    Under Wyeth v. Levine, 555 U.S. 555 (2009), and PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), failure-to-warn claims targeting a pharmaceutical are preempted unless the manufacturer could have provisionally…

  4. Drug Injury Watch

    Beovu Drug Label Change in December 2021 Adds More Information About Vision Loss Side Effects

    By Tom Lamb

    Provides "risk factors and possible mechanism" for Beovu-related Retinal Vasculitis and Retinal Vascular Occlusion   (Posted by Tom Lamb at Drug Injury Watch)   We have finally seen the first Beovu drug label…

  5. Drug & Device Law

    D.N.J. Dismisses Drug Consumer Fraud Action on Preemption Grounds

    By Stephen McConnell

    A lot of life comes down to timing. Maybe you submitted your job application just as positions were opening. Maybe a slow taxi driver caused you to miss a disaster.…

  6. Mass Tort Defense

    Drug Claims Preempted – Lack of Newly Acquired Evidence

    By Sean Wajert

    Today's post looks at Rayes v. Novartis Pharms. Corp., No. EDCV21201JGBKKX, 2021 WL 2410677 (C.D. Cal. June 11, 2021), which contains an interesting discussion of an aspect of drug product preemption. …

  7. Big Molecule Watch

    Introduction To Biosimilars And Labeling Issues (For The Defense)

    By Big Molecule Watch

    As biosimilars begin to gain traction in the U.S. pharmaceutical market, the distinct labeling requirements applicable to them are likely to affect product liability litigation in this area, raising implications…

  8. Drug & Device Law

    Guest Post – E-Gads, Once Again Preemption Prevails In Gadolinium Contrast Litigation

    By Bexis

    Here's another guest post by Reed Smith's Dean Balaes.  This one looks into a major (but not too recent) post-Albrecht drug preemption case.  Can't have too many of those!  As…

  9. Drug & Device Law

    Guest Post – Paint It Black: The Ninth Circuit OKs RICO Liability For Failure To Warn About Drug Safety Risks

    By Bexis

    Today's guest post, about a bottom-ten RICO third-party payor action from (no surprise) the Ninth Circuit, is by long-time friend of the blog (and blogger in his own right), Jonah…

  10. Drug & Device Law

    Redistribute This!

    By Bexis

    Back in 2012, we published our “Distribute This!” post about In re Fosamax (Alendronate Sodium) Products Liability Litigation (No. II), 2012 WL 181411 (D.N.J. Jan. 17, 2012), lauding its ruling…